Jones Financial Companies Lllp Buys Shares of 26,120 Zoetis Inc. $ZTS

Jones Financial Companies Lllp purchased a new position in Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, Holdings Channel reports. The fund purchased 26,120 shares of the company’s stock, valued at approximately $1,877,000.

Other institutional investors and hedge funds have also modified their holdings of the company. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Zoetis in the 2nd quarter worth $25,000. Dunhill Financial LLC raised its holdings in Zoetis by 519.3% in the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after purchasing an additional 296 shares during the period. Prosperity Bancshares Inc purchased a new position in Zoetis during the fourth quarter valued at $25,000. Cassaday & Co Wealth Management LLC purchased a new position in Zoetis during the first quarter valued at $28,000. Finally, Root Financial Partners LLC grew its holdings in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $77.13 on Tuesday. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The company’s fifty day moving average price is $75.70 and its 200-day moving average price is $96.81. Zoetis Inc. has a one year low of $71.00 and a one year high of $157.21. The company has a market capitalization of $31.87 billion, a PE ratio of 12.71, a price-to-earnings-growth ratio of 1.82 and a beta of 0.73.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. Zoetis’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Analyst Ratings Changes

ZTS has been the subject of a number of analyst reports. Citigroup reduced their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Barclays cut their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. HSBC reduced their target price on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday, July 6th. William Blair restated a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Finally, Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $109.23.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.